Endocrinology, Vol 118, 2137-2143, Copyright © 1986 by Endocrine Society

ARTICLES

On the fate of centrally administered somatostatin in the rat: massive hypersomatostatinemia resulting from leakage into the peripheral circulation has effects on growth hormone secretion and glucoregulation

GS Tannenbaum and YC Patel

We examined the effects of intracerebroventricular (icv) administration of the somatostatin peptides, S-14 and S-28, and an analog, [D-Trp22]S- 28, on spontaneous GH and glucose secretion in freely moving rats bearing chronic icv and intraatrial cannulae. Normal saline icv-treated control rats exhibited the typical pulsatile pattern of GH secretion. Central injection of S-14, S-28, and [D-Trp22]S-28 (each at two different doses, 5 and 10 micrograms) caused an early significant suppression of plasma GH levels which was of longer duration after S-28 or [D-Trp22]S-28 than after S-14 injection. The icv administration of S- 28 and [D-Trp22]S-28 (but not S-14) also resulted in significant hyperglycemia, which persisted for periods up to 1 h. In a second study designed to determine whether somatostatin administered via the brain ventricle can reach the peripheral circulation, we measured plasma levels of S-14-like immunoreactivity (S-14 LI) and S-28-(15-28) LI at frequent time intervals after icv injection of S-14 (5 micrograms) and S-28 (10 micrograms). Plasma S-14 LI rose from a basal value of 0.16 +/- 0.02 (+/- SE) ng/ml to a peak of 3.0 +/- 1.0 ng/ml at 1 min, and S-28 icv resulted in a 150-fold increase in plasma S-28-(15-28) LI 1 min after injection. Sephadex G-50 gel chromatography revealed that the plasma immunoreactivity consisted of a single molecular species (either S-14 or S-28) corresponding to the centrally administered counterpart. These results demonstrate that after icv administration at high doses, both forms of somatostatin cause an acute inhibition of spontaneous GH secretion and that the larger form also causes hyperglycemia. We correlate these events with massive hypersomatostatinemia resulting from leakage of the somatostatin peptides from the cerebrospinal fluid into the systemic circulation. The findings indicate that icv injected hypothalamic hormones can reach the peripheral circulation and exert significant biological actions on distant target organs; thus, they have important implications for the design and interpretation of experiments in which peptides are administered via the cerebral ventricles.

This article has been cited by other articles:

				H. D. Sun, M. Malabunga, J. R. Tonra, R. DiRenzo, F. E. Carrick, H. Zheng, H.-R. Berthoud, O. P. McGuinness, J. Shen, P. Bohlen, et al. Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E964 - E976. [Abstract] [Full Text] [PDF]

				V. Martínez, J. Rivier, D. Coy, and Y. Taché Intracisternal Injection of Somatostatin Receptor 5-Preferring Agonists Induces a Vagal Cholinergic Stimulation of Gastric Emptying in Rats J. Pharmacol. Exp. Ther., June 1, 2000; 293(3): 1099 - 1105. [Abstract] [Full Text]

				L. Beranek, I. Hajdu, J. Gardi, P. Taishi, F. Obal Jr., and J. M. Krueger Central administration of the somatostatin analog octreotide induces captopril-insensitive sleep responses Am J Physiol Regulatory Integrative Comp Physiol, November 1, 1999; 277(5): R1297 - R1304. [Abstract] [Full Text] [PDF]

				M. Masuda, S. Kanai, and K. Miyasaka Inhibitory effect of central dopamine on basal pancreatic secretion in conscious rats Am J Physiol Gastrointest Liver Physiol, January 1, 1998; 274(1): G29 - G34. [Abstract] [Full Text] [PDF]

				K. Aurang, J. Wang, and K. C. K. Lloyd Somatostatin Inhibition of Acid and Histamine Release by Activation of Somatostatin Receptor Subtype 2 Receptors in Rats J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 245 - 252. [Abstract] [Full Text]